Codexis (CDXS)

A major focus for Codexis is biocatalysis for small-molecule drug production. In this area, its enzymes are used to improve manufacturing routes for active pharmaceutical ingredients and intermediates. Enzyme-based processes can help drugmakers reduce waste, simplify production steps, improve yield, and support more sustainable manufacturing. Codexis has historically worked with pharmaceutical partners that require custom catalysts for commercial or development-stage medicines.

The company is also building its ECO Synthesis platform, which is aimed at the production of RNA interference therapeutics. This platform applies enzymatic methods to the large-scale manufacture of RNAi molecules, a field where production efficiency and quality are important as nucleic-acid medicines move through development and commercialization.

Codexis generates most of its revenue from the Americas, and its business model can include research and development collaborations, technology access, enzyme supply, and milestone or commercial arrangements depending on the program. The company occupies a specialized position at the intersection of biotechnology, synthetic chemistry, and pharmaceutical process development. Investors typically evaluate Codexis by looking at the adoption of its enzyme platforms, progress with pharma partners, revenue visibility from manufacturing applications, research spending, and the commercial potential of its ECO Synthesis technology.